Efficacy of a tailored approach with nivolumab (N) and nivolumab plus ipilimumab (N plus I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC

被引：0
|
作者：
Grimm, M-O. [1 ]
Schostak, M. [2 ]
Gruen, C. B. [3 ]
Loidl, W. C. [4 ]
Pichler, M. [5 ]
Zimmermann, U. [6 ]
Schmitz-Draeger, B. J. [7 ]
Steiner, T. [8 ]
Roghmann, F. [9 ]
Niegisch, G. [10 ]
Schmitz, M. [11 ]
Baretton, G. [12 ]
Leucht, K. [1 ]
Schumacher, U. [13 ]
Foller, S. [14 ]
Zengerling, F. [15 ]
Meran, J. [16 ]
机构：
[1] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[2] Magdeburg Univ Hosp, Dept Urol, Magdeburg, Germany
[3] Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[4] Elisabethinen Hosp, Dept Urol, Linz, Austria
[5] Graz Univ Hosp, Dept Oncol, Graz, Austria
[6] Greifswald Univ Hosp, Dept Urol, Greifswald, Germany
[7] St Theresien Krankenhaus, Urol 24, Nurnberg, Germany
[8] Helios Hosp Erfurt, Dept Urol, Erfurt, Germany
[9] Univ Hosp Ruhr Univ Bochum, Marien Hosp Herne, Dept Urol, Herne, Germany
[10] Heinrich Heine Univ Dusseldorf, Dusseldorf Univ Hosp, Dept Urol, Dusseldorf, Germany
[11] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Immunol, Dresden, Germany
[12] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Pathol, Dresden, Germany
[13] Friedrich Schiller Univ Jena, Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[14] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[15] Ulm Univ Hosp, Dept Urol, Ulm, Germany
[16] Hosp Barmherzige Brueder, Dept Internal Med Hematol & Internal Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2372P
引用
收藏
页码：S1207 / S1208
页数：2
相关论文
共 50 条
  • [31] Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P plus A) or ipilimumab plus nivolumab (I plus N).
    Shah, Neil J.
    Shinde, Reshma
    Moore, Kristin
    Sainski-Nguyen, Amy
    Le, Lisa
    Cao, Feng
    Song, Rui
    Singhal, Puneet
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] 6y update of 1L nivolumab plus ipilimumab (N plus I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227
    Nishio, M.
    Ramalingam, S. S.
    Ciuleanu, T.
    Caro, R. Bernabe
    Mizutani, H.
    Lee, J.
    Audigier-Valette, C.
    Sangha, R.
    Urban, L.
    Burgers, J. A.
    Pluzanski, A.
    Lee, K. Hyeong
    Zurawski, B.
    Schenker, M.
    Peters, S.
    Paz-Ares, L. G.
    Borghaei, H.
    O'Byrne, K. J.
    Brahmer, J. R.
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Yuan, Y.
    Blum, S. I.
    Reck, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1327 - S1327
  • [33] A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N plus I) or nivolumab plus chemotherapy (N plus CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.
    Chau, Ian
    Bridgewater, John A.
    Wyrwicz, Lucjan
    Greenwood, Mike
    Blum, Steven I.
    Moreno-Koehler, Alejandro
    Worthy, Gill
    Taylor, Fiona
    Davis, Catherine
    Chen, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 251 - 251
  • [34] Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
    Jain, Rohit K.
    Yang, Yuanquan
    Chadha, Juskaran
    Zhang, Jingsong
    Raymond, Sarah
    Oschmann, Erika
    Poehlman, Trey
    Fan, Wenyi
    Kim, Youngchul
    Dhillon, Jasreman
    Chahoud, Jad
    Chatwal, Monica Sheila
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS713 - TPS713
  • [35] Nivolumab (N) plus ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
    Argiris, A.
    Harrington, K.
    Tahara, M.
    Ferris, R. L.
    Gillison, M.
    Fayette, J.
    Daste, A.
    Koralewski, P.
    Nin, R. Mesia
    Saba, N. F.
    Mak, M.
    Avitia, M. A. Alvarez
    Guminski, A.
    Muller-Richter, U.
    Kiyota, N.
    Roberts, M.
    Khan, T. A.
    Miller-Moslin, K.
    Wei, L.
    Haddad, R. Robert
    ANNALS OF ONCOLOGY, 2021, 32 : S1310 - S1311
  • [36] FRACTION-RCC: innovative, high-throughput assessment of nivolumab plus ipilimumab (N plus I) for treatment-refractory advanced renal cell carcinoma (aRCC)
    Loidl, W.
    Choueiri, T. K.
    Kluger, H.
    George, S.
    Tykodi, S. S.
    Kuzel, T. M.
    Perets, R.
    Nair, S.
    Procopio, G.
    Carducci, M.
    Castonguay, V.
    Folefac, E.
    Lee, C. -H.
    Hotte, S. J.
    Miller, W. H.
    Saggi, S. S.
    Gold, D.
    Motzer, R. J.
    Escudier, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 209 - 209
  • [37] Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
    Kalirai, Austin
    Joy, Isaiah
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Hansen, Aaron Richard
    Thana, Myuran
    Graham, Jeffrey
    Heng, Daniel Yick Chin
    Castonguay, Vincent
    Bjarnason, Georg A.
    Breau, Rodney H.
    Kapoor, Anil
    Pouliot, Frederic
    Wood, Lori
    Basappa, Naveen S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
    Haddad, Robert I.
    Harrington, Kevin
    Tahara, Makoto
    Ferris, Robert L.
    Gillison, Maura
    Fayette, Jerome
    Daste, Amaury
    Koralewski, Piotr
    Zurawski, Bogdan
    Taberna, Miren
    Saba, Nabil F.
    Mak, Milena
    Kawecki, Andrzej
    Girotto, Gustavo
    Alvarez Avitia, Miguel Angel
    Even, Caroline
    Toledo, Joaquin Gabriel Reinoso
    Guminski, Alexander
    Muller-Richter, Urs
    Kiyota, Naomi
    Roberts, Mustimbo
    Khan, Tariq Aziz
    Miller-Moslin, Karen
    Wei, Li
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2166 - +
  • [39] First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
    Baclin, Firas
    Carbone, David P.
    Ciuleanu, Tudor-Eliade
    Schenker, Michael
    Cobo-Dols, Manuel
    Bordenave, Stephanie
    Juan-Vidal, Oscar
    Menezes, Juliana
    Reinmuth, Niels
    Richardet, Eduardo
    Cheng, Ying
    Mizutani, Hideaki
    Paz-Ares, Luis G.
    Lu, Shun
    John, Thomas
    Zhang, Xiaoqing
    Hu, Nan
    Bantu, David
    Baxi, Vipul
    Neely, Jaclyn
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E51 - E51
  • [40] In-situ immune markers predict nivolumab (N) plus /-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
    Meylan, M.
    Sun, C-M.
    Elaidi, R-T.
    Moreira, M.
    Bougouin, A.
    Verkarre, V.
    Bennamoun, M.
    Chevreau, C. M.
    Borchiellini, D.
    Barthelemy, P.
    Pannier, D.
    Maillet, D.
    Goupil, M. Gross
    Tournigand, C.
    Braychenko, E.
    Phan, L.
    Oudard, S.
    Fridman, W-H.
    Sautes-Fridman, C.
    Vano, Y-A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1207 - S1207
12345